Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UKALL 2003: Treatment Optimization for Childhood ALL
NCT00222612Phase 4Unknown
- Sponsor
- University of Oxford
- Start
- Oct 2003
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Targeted Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vincristine sulfate liposome injection, dexamethasone, pegylated liposomal doxorubicin, daunorubicin, pegaspargase and 4 more in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by University of Oxford. Primary endpoint: Event Free Survival at 5 years. Status: unknown.
02
Drugs
vincristine sulfate liposome injectiondexamethasonepegylated liposomal doxorubicindaunorubicinpegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00222612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00222612.